

ASX RELEASE | OSTEOPORE LIMITED

SHORTFALL OVERSUBSCRIBED AHEAD OF OSTEOPORE'S GLOBAL EXPANSION

20 June 2023: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), a leading provider of innovative regenerative implants that enable natural tissue regeneration, is pleased to announce that it has received firm commitments for the completed placing of all the shortfall shares from the non-renounceable entitlement offer announced to ASX on 13 March 2023.

Osteopore received strong interest in the shortfall with firm commitments received for A\$908,660, resulting in the scaling back of many applications in accordance with section 1.3 of the prospectus announced to ASX on 13 March 2023 (“Prospectus”).

A total of 10,690,122 new fully paid ordinary shares will be placed at an issue price of A\$0.085. Osteopore will also issue 1 free attaching listed option (“Option”) (ASX: OSXO) for every 1 new share subscribed for. These Options are exercisable at A\$0.225 and have an expiry of 24 April 2026. In accordance with the terms of the Company’s Prospectus and Listing Rule 7.2 Exception 3, the Company must issue the shortfall securities by no later than 17 July 2023. This capital injection signifies the heightened interest in Osteopore’s potential for continued growth and innovation. The funds raised will give Osteopore a solid runway in the new financial year, and be deployed strategically to facilitate international market expansion, bolster Osteopore's ongoing research & development initiatives, and drive the production of next-generation 3D printed biomimetic bone implants.

Osteopore Executive Chairman, Mark Leong said:

"This successful funding round highlights the robust confidence of our investors in our vision and capabilities. The additional capital will help accelerate our mission to revolutionise the bone healing process and provide innovative and effective solutions for millions of patients worldwide."

Osteopore wishes to express its gratitude to its shareholders for their ongoing support. As we continue to forge ahead, we are committed to delivering enhanced shareholder value and industry-changing solutions in bone regeneration.

Cadmon Advisory Pty Ltd (“Cadmon”) acted as the sole lead manager to both the non-renounceable entitlement and shortfall offer resulting in a total of A\$2,633,616 raised for the Company. The Company will issue 5,000,000 Quoted Options (ASX:OSXO) to Cadmon (and/or its nominees) as consideration for the Company placing all shortfall securities, as detailed in the Prospectus.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of products specifically engineered to facilitate natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants. Our 3D printer technology is not available in the market and unique to Osteopore.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.